abstract |
An alpha 2 adrenergic receptor agonist can be used in the manufacture of a medicament for intravitreal administration in the treatment of retinal diseases and ocular afflictions. In an embodiment the alpha 2 adrenergic receptor agonist has formula (I), wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy. |